

Abstract

Editas Medicine is working to develop therapies to correct the underlying cause of genetic diseases using the CRISPR-Cas9 system.


CRISPR-Cas9 is an RNA-guided DNA endonuclease where an ~100 nucleotide guide RNA (gRNA) is complexed with the ~135 kDa Cas9 protein to target it to the site of the genetic mutation. In the case of ex vivo gene editing therapies, isolated patient cells will be modified by direct delivery of the Cas9 ribonucleoprotein complex (RNP).

These approaches will require a detailed characterization of the RNP complex and its constituent Cas9 protein and gRNA.


Here we highlight the effect of gRNA folding behavior for the proper formation of functional RNP complexes. We use differential scanning fluorimetry (DSF), a fluorescence-based assay that monitors the thermal unfolding transition of the Cas9 RNP complex as a qualitative method to characterize RNP complexes.

Towards developing a quantitative assay for gRNA folding we describe using bio-layer interferometry to measure the response rate (signal intensity) resulting from the interaction of folded and unfolded gRNA with the Cas9 protein.


Finally the in vitro biochemical activity and cellular potency of these RNP complexes were measured to correlate the biophysical measurements with activity of the complexes. Improperly folded gRNA lower the stability of RNP complexes and show lower biochemical and cellular potency.



1. Differential scanning fluorimetry and Bio-layer interferometry




2. gRNA truncations alter RNP stability and activity




Disclosure: This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the Company's strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "may," "might," "plan," "potential," "predict," "project," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this presentation include statements regarding the Company's goals of submitting an IND for the LCA10 program in 2017, initiating an LCA10 natural history study in mid-2017, achieving preclinical proof-of-concept for additional programs and establishing alliances. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and critical development of the Company's product candidates; clinical trial; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other factors discussed in the "Risk Factors" section of the Company's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.


3. Effect of gRNA folding on RNP stability and activity



4a. BLI can be used to discern folded and mis-folded gRNA



4b. DSF can distinguish folded and mis-folded gRNA-RNPs



Conclusions

We demonstrate the use of DSF and BLI as two key methods of quality control to our RNP-based gene editing therapeutics. Furthermore, RNPs composed of folded or misfolded gRNA show differing stability and cellular editing efficacies